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Objective: To scrutinize patterns of multi-drug-resistant uropathogenic Escherichia coli
(UPEC) strains and particularly of ﬂuoroquinolone-resistance this is an alternative choice
for the treatment of urinary tract infections.
Methods: Bacterial samples (n = 250) were collected from out-patients from August 2012
to August 2014 Islamabad. Antibiotic susceptibility proﬁling and determination of mini-
mum inhibitory concentrations (MICs) and minimum bactericidal concentrations were
performed according to the guidelines of Clinical and Laboratory Standards Institute (CLSI,
2012). Genes, qnrA, qnrB and qnrS were identiﬁed by DNA ampliﬁcation and sequencing.
Results: The highest percentage of UPEC isolates were resistant to co-trimoxazole
(82%) followed by cephalothin (80%), 2nd Gen, 3rd Gen and 4th Gen cephalosporins,
respectively. Resistance against gentamicin, amikacin remained 29% and 4%. For other
drugs including nitrofurantoin, tetracycline, carbapenem and beta-lactam inhibitors
remained below 10%. Altogether, 59% of the isolates were resistant to at least three
antibiotics including one ﬂuoroquinolone. Overall, MICs for ciproﬂoxacin remained
(MIC  256 mg/mL) and for levoﬂoxacin (MIC  16 mg/mL and 32 mg/mL). No
signiﬁcant differences were observed regarding MIC values of extended spectrum
b-lactamase (ESBL) and non-ESBL producers. For qnrS and qnrB positive isolates MICs
remained above 32 mg/mL. Prevalence of UPEC was signiﬁcantly higher among females
and 40% of the isolates were ESBL producers.
Conclusions: Higher percentages of ESBL producing UPEC were associated with uri-
nary tract infections. Moreover, the majority of these isolates were multi-drug resistant
and ﬂuoroquinolone-resistant.1. Introduction
Uropathogenic Escherichia coli (E. coli) (UPEC) is one of
the most common cause of urinary tract infections (UTIs)
worldwide. A substantial amount of surveillance data indicates
the prevalence of trimethoprim-sulfamethoxazole (TMP-SMX)
resistant-UPEC strains [1–3]. Eventually, ﬂuoroquinolone has
become an alternative therapeutic choice for the treatment [3].However, recently the prevalence of ﬂuoroquinolone-resistance
among uropathogenic strains has also been reported in
different regions [1–3]. Particularly, in the Asian-Paciﬁc region
and in India, the prevalence of extended spectrum b-lactamases
(ESBL) producing ﬂuoroquinolone-resistant uropathogenic
strains is signiﬁcantly higher [4].
Fluoroquinolone-resistance is conferred by different molec-
ular mechanisms including chromosomal mutations in DNA
gyrase and/or topoisomerase IV, porins and/or efﬂux pumps
genes. In addition, members of the pentapeptide repeat family of
proteins encode plasmid-mediated quinolones resistance. The
ﬁrst member of this family of proteins is known as QnrA, which
was identiﬁed in USA two decades earlier [5]. Several other
genetic determinants belonging to this pentapeptide repeat
family of proteins include QnrB, QnrC, QnrD and QnrS which
were identiﬁed in subsequent years [5]. These molecular
factors have wide distribution and were mostly reported inn access article under the CC BY-NC-ND
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the homologues of Qnr-like proteins were also reported in other
bacterial species including Mycobacterium, Enterococcus, Lis-
teria, colistridia and recently, a new member of the same protein
family was identiﬁed in Stenotrophomonas maltophilia, anno-
tated as Smqnr [4].
Global epidemiological studies indicate the prevalence of
multi-drug resistant (MDR) ESBL producing Enterobacteriaceae
both in the community acquired and healthcare facility associ-
ated infections [6–10].
Previously, from Asian regions, several studies focused on the
prevalence of ESBL producing UPEC, which is known to be
associatedwith 90%of the community acquired and approximately
50% of the nosocomial UTIs worldwide [11]. In Pakistan, over the
last decade, an increase in resistance against quinolones has been
witnessed in other bacterial species [12–16]. However, not much is
known about the ﬂuoroquinolone-resistance in ESBL producing
UPEC strains and its co-relation with plasmid encoded qnr genes.
2. Materials and methods
2.1. Bacterial strains and antimicrobial agents
Bacterial isolates under scrutiny (n = 250) were collected from
out-patients of the Pakistan Institute of Medical Sciences Islam-
abad during the period of August 2012 to August 2014. The
experimental work was approved by the Ethical Committees of
the hospital and in compliance with recommendations of the
Ethical Committees Committee; privacy was maintained
regarding patient data. Patients were of different age groups and
from different geographical locations across the country. Avail-
able clinical history and associated symptoms were registered for
the record. The identiﬁcation of UPEC was performed according
to the standard microbiological and biochemical protocols [17].
Antibiotic susceptibility proﬁling was performed by using
Muller-Hinton agar (Oxide, England), according to the Clinical
and Laboratory Standards Institute (CLSI) guideline provided in
year 2013 [18]. The antibiotic discs were purchased from
Bioanalyse (Turkey). The names and concentrations of
antibiotic discs are as follows; TMP-SMX (1.25 mg TMP,
23.75 mg SMX), ciproﬂoxacin (5 mg), sparﬂoxacin (10 mg),
norﬂoxacin (10 mg), levoﬂoxacin (5 mg), cepﬁme (30 mg), cef-
tazidime (30 mg), cefotaxime (30 mg), ceﬁxime (5 mg), cefurox-
ime (30 mg), cephalothine (30 mg), gentamicin (10 mg), amikacin
(30 mg), and augmentin: amoxicillin-clavulanic acid (30 mg),
nitrofurantoin (300 mg), sulzone: cefoperazone-sulbactum
(105 mg), tigecycline (15 mg), minocycline (30 mg), meropenem
(10 mg), aztreonam (30 mg), tazocin: tazobactum-piperacillin
(110 mg). To conﬁrm the prevalence of (ESBL) producing iso-
lates, phenotypic tests were performed by using discs of
amoxicillin-clavulanic acid, cefotaxime, ceftazidime and man-
obactum (aztreonam). For testing antibiotic susceptibility Muller-
Hinton agar (Oxide, England) was used by following the Kirby
Bauer disc-diffusion method as described in CLSI guidelines [18].
2.2. Determination of MICs and MBCs for levoﬂoxacin
and ciproﬂoxacin
Antibacterial activity of levoﬂoxacin and ciproﬂoxacin were
determined by measuring minimum inhibitory concentrations
(MICs). For these measurements micro-dilution broth method
was used as described by CLSI guidelines [18]. Brieﬂy, anadjusted inoculum of the test organism was inoculated into
Muller-Hinton broth (Oxoid, Basingstoke, UK) containing two
fold serial dilution of an initial antibiotic solution, each well
contained approximately 5 × 105 CFU/mL. Bacterial cultures
were tested against several antibiotic dilutions: 256, 128, 64, 32,
16, 8, 4, 2, 1, 0.5, 0.25 and 0.125 mg/mL. The cultures were
incubated for 18 h at 37

C, prior to make any observations and
upon inhibition of visible growth, the lowest concentrations of
antimicrobial agents responsible for inhibition were considered
MICs. By deﬁnition, minimum bactericidal concentration
(MBC) was considered to be the concentration of drug at which
99.9% reduction in the colony forming unit has been recorded
when comparing with the original inoculums. Determination of
MBCs was carried out by platting 0.01 mL from the tube having
no visible growth on Muller-Hinton agar plate (Oxide, England)
after 18–24 h of incubation at 37

C and was deﬁned as the
concentration that reduced the colony forming units up to 99.9%
in comparison to original inoculums. The strain of E. coli ATCC
25922 was used as quality control. The breakpoints for the
resistance against ciproﬂoxacin were 4 mg/L and for levo-
ﬂoxacin 8 mg/L according to the CLSI guidelines [18].
2.3. DNA extraction and ampliﬁcation of qnrA, qnrB
and qnrS genes
Bacterial DNA extraction was performed by phenol-
chloroform method [19] and the qualitative analysis of the
DNA was performed by directly visualizing on agarose gel
(Sigma, Germany). After conﬁrmation, eighty-ﬁve quinolones
resistant strains were screened for the presence of qnrA, qnrB
and qnrS genes by using previously reported sets of primers and
PCR conditions [19].
2.4. DNA sequencing of qnrA, qnrB and qnrS genes
The ampliﬁed products were puriﬁed by using (Gel Band
Puriﬁcation Amersham, USA) DNA sequencing was done by
automated DNA sequencing system (ABI 3130, Perkin–Elmer
Applied Biosystems, Foster city, California). The electrophero-
gram of sequenced DNA was analyzed by Chromas 2.23
(Technelysium, Queensland, Australia). Protein and nucleotide
sequence similarity were analyzed by using BLAST (Basic
Local Alignment Search Tool 138.0). DNA sequences were
submitted to GenBank database which were assigned following
accession numbers KR698789, KR698790, KR698791,
KR698792, KR698793.
2.5. Statistical analysis
The antibiotic resistance data was recorded in MS-Excel and
the statistical analysis of the data was performed through
GraphPad Prism, version 5 and statistical signiﬁcance between
different parameters was checked by Chi-square test, t-test and
ANOVA at a cut-off value of P < 0.05.3. Results
3.1. Prevalence of antibiotic resistance among UPEC
Altogether, 148 samples were conﬁrmed as UPEC, antibiotic
resistance was checked against cephalosporins (1st Gen, 2nd
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quinolones, nitrofurantoin, monobactams, sulfonamides, gly-
cylcyclines, tetracycline and beta-lactamase inhibitors. The
highest percentage of isolates was resistant to co-trimoxazole
(82%) and cephalosporin (80%), 1st Gen, cephalothin that was
followed by other generation of cephalosporin (Table 1).
Seventy-one percent of the tested isolates were resistant to
amoxicillin-clavulanic acid. Resistance against gentamicin
remained 29% while against amikacin 4%. The percentage of
resistance against other antibiotics including nitrofurantoin,
tetracycline, carbapenem and b-lactam inhibitors remained
below 10% (Table 1). A total of 59% of the isolates showed
resistant to at least three antibiotics including ﬂuoroquinoloneTable 1
Numbers and percentages of antibiotic resistant UPEC isolates. n (%).
Antibiotic Resistant isolates ESBL producers
Ciproﬂoxacin 90 (60.8) 46 (51.1)
Sparﬂoxacin 89 (60.1) 46 (51.6)
Levoﬂoxacin 91 (61.4) 46 (50.5)
Norﬂoxacine 87 (58.7) 46 (52.8)
Amikacin 6 (4.0) 2 (33.3)
Gentamicin 43 (29.0) 19 (44.1)
Aztreonam 80 (54.0) 53 (66.2)
Cephalothine 119 (80.0) 58 (48.7)
Ceﬁxime 94 (63.5) 58 (61.7)
Cefuroxime 92 (62.1) 58 (63.0)
Cefotaxime 94 (63.5) 57 (60.6)
Ceftazidime 91 (61.4) 57 (63.0)
Cepﬁme 86 (58.1) 55 (64.0)
Tigecycline 1 (0.6) 1 (100.0)
Minocycline 13 (8.7) 11 (85.0)
Piperacillin tazobactam 7 (4.7) 2 (29.0)
Sulzone 11 (7.4) 7 (64.0)
TMP-SMX 122 (82.0) 57 (47.0)
Meropenem 2 (1.3) 1 (50.0)
Nitrofurantoin 9 (6.0) 4 (44.4)
Fosfomycin 15 (10.0) 6 (40.0)
Amoxicillin-clavulanic acid 105 (71.0) 57 (54.2)
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Figure 1. Age (a) and gender (b) wise prevalence of ﬂuoroquinolone-MDR
UPEC.and were therefore named as ﬂuoroquinolone MDR (Figure 1a,
b). The overall rate of resistance towards ﬂuoroquinolone
remained 61% (n = 91). Individually, the rate of resistance
against ciproﬂoxacin, sparﬂoxacin, levoﬂoxacin and norﬂoxacin
remained 60%, 59%, 58% and 57%, respectively. Overall, the
prevalence of UPEC was signiﬁcantly higher among female
patients in comparison to the male patients (Figure 1b). How-
ever, distribution of the ﬂuoroquinolone-resistant isolates was
found to be signiﬁcantly higher among the male patients
P < 0.05 (Figure 2a). Observed patterns of ﬂuoroquinolone-
resistant MDR isolates are shown among different age groups
of the patients (Figure 1a). Overall, higher numbers of isolate
were MDR (Figures 3 and 4). The distribution of the MDR
isolates among different genders and age groups is shown in
(Figure 5a, b). Out of all tested isolates 40% of the isolates
(n = 59) were ESBL producers while remaining (n = 89) isolates
were non-ESBL producers.2.40
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Figure 2. Age (a) and gender (b) wise distribution of ﬂuoroquinolone-
MDR UPEC.
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Figure 3. Overall prevalence of MDR-UPEC in male and female patients.
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Figure 5. Overall distribution of MDR-UPEC among male and female
patients (a) and among different age groups (b).
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Figure 4. Overall prevalence of MDR-UPECs in different age groups.
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Two equal subset of the selected isolates each (n = 35)
ESBL producers and (n = 35) non-ESBL producers were tested
to determine MIC of ciproﬂoxacin and levoﬂoxacin, two most
commonly prescribed ﬂuoroquinolone antibiotics. Bacterial
isolates were tested against different concentrations of antibi-
otics ranging from 0.125 mg/mL to 256 mg/mL. Overall, MIC
values for ciproﬂoxacin remained signiﬁcantly higher
(MIC  256 mg/mL) for both ESBL producers and non-ESBL
producers (Figure 6a). In case of levoﬂoxacin however, MIC
values for the majority of the isolates fall between
(MIC  16 mg/mL and 32 mg/mL as shown in Figure 6c).
Similarly, MBCs for both antibiotics (ciproﬂoxacin and levo-
ﬂoxacin) were determined for both ESBL producers and14
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Figure 6. Ciproﬂoxacin MICs (a) and MBCs (b), and levoﬂoxacin MICs (c) anon-ESBL producers. Overall, the majority of isolates both
ESBL producers and non-ESBL producers showed MBC
value  256 mg/mL for ciproﬂoxacin (Figure 6b). In contrast
to ciproﬂoxacin for levoﬂoxacin, MBC value remained 64 mg/12
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ESBL producing isolates (Figure 6d). Overall, the differences
between ESBL producers and non-ESBL producers regarding
their MICs and MBCs values were not statistically signiﬁcant.
The mean distribution of MIC-ciproﬂoxacin, MBC-ciproﬂox-
acin, MIC-levoﬂoxacin and MBC-levoﬂoxacin is shown
(Figure 7). An independent comparison between mean values
of MIC-ciproﬂoxacin and MBC-ciproﬂoxacin, MIC-levo-
ﬂoxacin and MBC-levoﬂoxacin conﬁrmed signiﬁcant differ-
ences (P < 0.0001). Spearman's rank correlation was
established between MIC and MBC values of ciproﬂoxacin
and levoﬂoxacin that showed that these differences were not
more than fourfold in any case (Figure 8a, b). Similarly, theMIC-CIP   MBC-CIP  MIC-LEV MBC-CIP MIC-CIP  MBC-CIP MIC-LEV MBC-LEV
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Figure 7. Mean distribution of MICs and MBCs of ciproﬂoxacin and
levoﬂoxacin.
 
300
250
200
150
100
50
0
350
300
250
200
150
100
50
0
M
BC
-c
ip
ro
flo
xa
ci
n
M
B
C
- le
vo
flx
ac
in
 
0           50           100        150         200         250       300
0             50          100         150          200         250        300
a
b
Figure 8. Spearman's rank correlation established between MIC and MBC
values of ciproﬂoxacin (a) and levoﬂoxacin (b).difference between MIC-ciproﬂoxacin and MIC-levoﬂoxacin
were statistically signiﬁcant (P < 0.0001).
3.3. Detection and DNA sequencing of qnrA, qnrB and
qnrS genes
All the ﬂuoroquinolone-resistant isolates (n = 91) were
screened for the presence of plasmid-mediated quino-
lones resistance genes out of which 2 (2.35%) were found to
carry qnrB gene while three (3.53%) were found to carry qnrS
gene. None of the sample was positive for qnrA gene. Overall,
MICs for qnrS and qnrB positive isolates remained above
32 mg/mL.
4. Discussion
In this study, the highest percentage of isolates was resistant
to TMP-SMX which was widely used as a ﬁrst treatment choice
for UTI infections [20]. For this class of antibiotics, similar
trends have previously been noticed [1,2]. Due to the higher
percentage of resistance, in some countries use of TMP-SMX
has become limited. For example, German national guide-
lines do not recommend this agent as a ﬁrst choice for the
treatment of uncomplicated cystitis [21]. Since TMP-SMX
resistance is associated with the development of concomitant
resistance to other antibiotics thereof, limited use of TMP-
SMX may help to sustain its effectiveness over the long run.
Other than TMP-SMX, uncomplicated acute cystitis in female
patients is treated with nitrofurantoin, however it is not rec-
ommended for the patients with pyelonephritis [22]. Overall rate
of resistance against nitrofurantoin remained low in this
study, therefore, our ﬁnding reiterates that nitrofurantoin is a
suitable empiric choice for the treatment of acute cystitis in
this region.
Along with other antibiotics, resistance against ﬂuo-
roquinolone is of particular interest because it is frequently
recommended for the treatment of complicated cystitis in fe-
male patients. In this study, the overall prevalence of ﬂuo-
roquinolone-resistant isolates is higher in female patients. Vice
versa, given the small numbers of male UTI cases, overall
distribution of ﬂuoroquinolone-resistant isolates is higher
among male patients. Fluoroquinolones are also used as a ﬁrst
choice for the treatment of UTIs in men, mainly because of
certain advantages of this antibiotic over co-amoxiclav,
particularly in terms of its pharmacokinetic properties [23,24].
Taken together, in this study 59% of the isolates were
ﬂuoroquinolone-resistant, indicating considerable constraints
on treatment options particularly for complicated cystitis.
ESBL producing ﬂuoroquinolone-resistant uropathogenic
strains have signiﬁcantly been increased in the Asian-Paciﬁc
region and particularly in India [4]. Upon scrutiny, 40% of
the isolates were ESBL producers in this study and equal
numbers of both ESBL producers and non-ESBL producers
were tested to determine MICs of ciproﬂoxacin and levo-
ﬂoxacin, both are most commonly prescribed ﬂuoroquinolone
across Pakistan. For ESBL producers, resistance to mono-
bactams and all four generations of cephalosporin ranged from
54% to 80.4% while resistance to co-amoxiclav remained 71%.
Furthermore, the majority of isolates were resistant to all three
classes of antibiotics. It is noteworthy, that frequent uses of
cephalosporin are linked with the selection of ESBL producers
in different regions [25].
Ihsan Ali et al./Asian Pac J Trop Biomed 2016; 6(1): 60–66 65Upon measurement of MICs and MBCs of ciproﬂoxacin and
levoﬂoxacin, no signiﬁcant differences were observed regarding
ESBL and non-ESBL producing isolates, though MICs values
for both groups remained signiﬁcantly higher. In case of both
antibiotics, MICs and MBCs differences did not exceed more
than three folds, generally for bactericidal drugs like ﬂuo-
roquinolone, MBCs do not exceed more than fourfold of MICs.
Overall, ciproﬂoxacin (MIC  256 mg/mL) MICs values were
signiﬁcantly higher. In case of levoﬂoxacin, MIC values
remained between MIC  16 mg/mL and 32 mg/mL. Fluo-
roquinolones have particular pharmacodynamic properties as
they exhibit bactericidal activity which is concentration-
dependent and have extended post antibiotic effects. However,
it is important to note that determination of MICs and MBCs
in vitro may provide insights about the antimicrobial activity of
drugs, however such ﬁndings have the least signiﬁcance
regarding the treatment of infected patients, mainly because
ﬂuctuating level of drug in the serum of the treated patients and
the numbers of bacteria at site of infection in vivo may pose
completely different scenario. Furthermore, during in vitro
measurement of MICs or MBCs bacterial growth is not static
that is normally the case in vivo. Nevertheless, in vitro deter-
mination of MICs and MBCs based on breakpoints differentiates
two populations (i.e. susceptible and resistant).
In this study, qnrB and qnrS genes were associated with low
level of ﬂuoroquinolone-resistance. Previously, several inde-
pendent reports conﬁrmed that Qnr-positive ESBL producer
isolates conferred low level resistance to quinolones particularly
because the key function of the Qnr proteins is to protect the
gyrase proteins. However, resistance mediated by these molec-
ular factors may facilitate co-selection of plasmid encoded
resistance to other antibiotics [26–28]. Conclusively, the problem
of antibiotic resistance has gained unprecedented momentum
worldwide, therefore important measures are mandatory to
ensure rational and well-informed use of antibiotics as are
taken in European Union. Overall, this report indicates a higher
prevalence of MDR and ESBL UPEC in this region and prev-
alence of qnr genes in UPEC is linked with the moderate level of
ﬂuoroquinolone-resistance.
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